Antimicrobial Resistance in Everyday Clinical Practice: Current Challenges and Practical Considerations

Search strategy

A literature search was conducted using multiple databases, including PubMed Central, and Google Scholar. Reports and policy documents from various health organizations, AMR action plans, and surveillance frameworks were also reviewed. The search primarily included studies published between 2010 and 2024. Seminal articles published prior to this period were included selectively. Search terms such as “antimicrobial resistance,” “antibiotic resistance,” “mechanisms of resistance,” “antimicrobial stewardship,” and “rapid diagnostics” were used alone and in combination.

Inclusion and exclusion criteria

Peer-reviewed original research articles, systematic reviews, meta-analyses, narrative reviews, large surveillance studies, and international or national guideline and policy documents published in English were eligible for inclusion. Studies focusing on bacterial AMR with implications for clinical management, public health policy, or stewardship interventions were included. Case reports, editorials without substantive data, opinion pieces, and studies focusing exclusively on non- bacterial pathogens were excluded unless they contributed important conceptual perspectives relevant to AMR.

How Antimicrobial Resistance Emerges and Spreads

Antimicrobial resistance is a natural evolutionary phenomenon that arises through genetic adaptation within microbial populations. Resistant traits may develop through spontaneous mutations or be acquired via horizontal gene transfer mechanisms such as conjugation, transformation, and transduction. Antibiotics use exerts selective pressure on bacterial populations by eliminating susceptible organisms and allowing resistant strains to survive and proliferate. Over time, these resistant organisms become increasingly dominant, facilitating the dissemination of resistance within healthcare settings and the community. Repeated and inappropriate antimicrobial exposure further accelerates this process, contributing to the resistance.^[4,5] Understanding this evolutionary basis is essential for appreciating the molecular mechanisms through which microorganisms evade antimicrobial activity.

Mechanisms of antimicrobial resistance

AMR develops through genetic mutations and horizontal gene transfer, which allows the bacteria to survive exposure to antimicrobial agents.^5,7 Key resistance mechanisms include enzymatic drug inactivation, alteration of antibiotic targets, reduced membrane permeability, and active efflux of antimicrobials.^5,7 Among these, β-lactamase production, particularly extended-spectrum β-lactamases (ESBLs) and carbapenemases, remains among the most clinically important mechanisms. ESBLs hydrolyze most penicillins, cephalosporins, and aztreonam, whereas carbapenemases can hydrolyze carbapenems and other β-lactam antibiotics. [Table 1].⁸ Structural alterations in penicillin-binding proteins (PBPs) underlie methicillin resistance in Staphylococcus aureus, while mutations in DNA gyrase and topoisomerase IV reduce fluoroquinolone binding and efficacy.⁵

Biofilm formation, especially in device-associated infections, further complicates treatment by reducing antimicrobial penetration and impairing host immune clearance.⁷ These resistance mechanisms may coexist within the same organism, resulting in multidrug-resistant (MDR) phenotypes that markedly restrict therapeutic options.^5,8,9 A clear understanding of these pathways is therefore critical for informed empiric therapy and effective tailoring of targeted antimicrobial treatment in clinical practice.

Drivers of antimicrobial resistance

Antimicrobial resistance is driven by sustained selective pressure created by inappropriate antibiotic exposure across human, animal, and environmental settings. Among these, misuse of antibiotics in human healthcare remains a major contributor.^10,11 A large proportion of antibiotics prescribed in outpatient settings are unnecessary, particularly for viral upper respiratory tract infections (URTIs), where antibiotics provide no clinical benefit.^3,10 Healthcare system factors further accelerate the spread of resistance. Inadequate infection prevention and control practices, such as poor hand hygiene, overcrowded wards, limited isolation facilities, and insufficient environmental cleaning, facilitate transmission of resistant pathogens within healthcare settings.^9,12 Global travel and international trade further compound this problem by enabling the rapid cross-border spread of resistant organisms.¹³ At the same time, progress in antimicrobial development has stagnated due to economic disincentives and regulatory challenges, leaving clinicians with an increasingly limited therapeutic arsenal against resistant infections.¹⁴

The problem extends well beyond human medicine. Widespread antimicrobial use in agriculture and veterinary practice plays a major role in amplifying resistance.¹⁵ Antibiotics are often administered to livestock not only for treatment, but also for disease prevention and growth promotion. This results in prolonged low-dose exposure that may favor the emergence and persistence of resistant organisms.¹⁵ These resistant bacteria, or the resistance genes they carry, can reach humans through direct animal contact, contaminated food products, or environmental pathways. Such interconnected transmission underscores the limitations of addressing AMR within clinical settings alone and highlights the need for a One Health approach that integrates human, animal, and environmental health.^1,3

Stewardship as a time-dependent clinical intervention

The first 48 -72 hours after starting antibiotics often provide an important stewardship checkpoint during which microbiological results, clinical trajectory, and diagnostic reassessment can guide modification of therapy^11,17 Failure to reassess therapy as new clinical or microbiological information becomes available may contribute to escalation inertia, whereby broad-spectrum antibiotics are continued despite diminishing justification.^2,11,17

Framing stewardship as an acute, time-sensitive decision- making process rather than a retrospective policy exercise, emphasizes clinician accountability at the bedside and reinforces the importance of structured reassessment. A practical framework for antibiotic prescribing and reassessment in routine clinical practice is presented in Figure 1.

Close

Figure 1: Clinical approach to antibiotic decision-making: Structured prescribing, reassessment, and optimization are central to effective antimicrobial stewardship.

Export to PPT

Cognitive biases driving inappropriate antibiotic prescribing

Inappropriate antibiotic prescribing is not solely a knowledge deficit but is strongly influenced by cognitive and behavioral biases that shape clinician decision-making under uncertainty.¹⁷ Action bias, the tendency to favor intervention over inaction, often leads clinicians to prescribe antibiotics “just in case,” particularly in ambiguous clinical scenarios. Fear of litigation and diagnostic error further reinforces defensive prescribing behaviors, while social pressures from patients or family members may subtly influence clinical judgment, especially in outpatient settings. Behavioral interventions grounded in behavioral economics, such as public commitment strategies and peer comparison feedback, may be useful in reducing inappropriate antibiotic prescribing without adverse patient outcomes.¹⁷ Recognizing and addressing these cognitive drivers represents an underutilized yet powerful avenue for stewardship, shifting the focus from guideline dissemination to behavioral modification.

Role of diagnostics in everyday clinical practice

Diagnostic testing plays a pivotal role in balancing timely antimicrobial therapy with resistance mitigation, yet its application in routine practice is constrained by logistical and economic realities. Traditional culture-based diagnostics remain the gold standard but are limited by delays that may require empiric broadspectrum antibiotic initiation, particularly in acutely ill patients.¹⁸ Biomarkers such as procalcitonin have emerged as useful adjuncts to support early antibiotic de-escalation, though their interpretation must be integrated with clinical judgment rather than used in isolation.¹⁸ Syndromic molecular PCR panels offer rapid pathogen identification and resistance gene detection, particularly in bloodstream infections. Their high cost, limited availability, and risk of overinterpretation in colonization rather than true infection remain important challenges However, resistance gene detection does not necessarily predict the complete phenotypic susceptibility profile and should be interpreted alongside conventional susceptibility testing.^17,18

Outpatient and primary care perspective

A substantial proportion of antibiotic prescriptions are issued in outpatient and primary care settings, making these important targets for antimicrobial stewardship.^10,19 In such environments, time constraints and fear of clinical deterioration contribute to precautionary prescribing.¹⁷ Strategies such as delayed antibiotic prescriptions, watchful waiting with clear safety net advice, and patient education regarding the natural course of self-limiting infections can help in reducing unnecessary antibiotic use without compromising patient satisfaction or outcomes, in selected patients.¹⁹ Embedding these approaches into routine primary care practice can help curb resistance at its most significant point of origin.